Since 1996, highly pathogenic avian influenza (HPAI) H5N1 virus has presented a persistent threat to public health. Its high degree of genetic diversity also poses enormous challenges in developing effective vaccines. To search for vaccine regimens that could elicit broadly neutralizing antibody responses against diverse HPAI H5N1 strains, in the present study we tested H5 hemagglutinin (HA) from an A/Thailand/1(KAN)-1/2004 strain in a heterologous prime-boost vaccination. We demonstrated that priming mice with DNA and boosting with virus-like particle induced antibody responses that cross-neutralize all reported clades and subclades of HPAI H5N1 viruses and protect mice from high lethal dose HPAI H5N1 challenge in both active and passive immunizations. Unexpectedly, cross-divergent H5 neutralizing antibodies are directed to the HA head and block both attachment and postattachment of virus entry. Thus, we conclude that as a promising pan-H5 vaccine candidate this prime-boost regimen could be further developed in ferrets and in humans.
Since 1996, the highly pathogenic avian influenza (HPAI) H5N1 virus has spread in a variety of domestic and wild birds and was sporadically transmitted to humans in Asia, Europe, and Africa. As of 7 March 2013, the World Organization for Animal Health had highlighted thousands of HPAI H5N1 outbreaks in poultry and wild birds in 63 countries [1] . As of 15 February 2013, 620 human H5N1 infections had been confirmed, resulting in 367 deaths [2] . Although to date the human cases have largely been infected by close contact with sick poultry and the isolated viruses still show characteristics of avian influenza viruses, H5N1 strains with enhanced binding affinity to the humantype receptor have been reported [3] . In addition, 2 highly publicized studies show that laboratory-adapted H5N1 variants with few amino acid residue mutations in hemagglutinin (HA) were able to spread through aerosol from infected to uninfected ferrets [4, 5] . Moreover, database search identified 2 H5N1 strains whose HA needs only 2 additional mutations to create variants with the transmissible feature identified in one of the above studies [6] . These findings raised serious concerns about the possible evolving of HPAI H5N1 virus to become transmissible among people and resulting in a global pandemic.
When spreading over much of the eastern hemisphere, HA of HPAI H5N1 viruses has evolved into 10 clades in various host species [7] . Among them, clade 2 is divided into 5 subclades (2.1, 2.2, 2.3, 2.4, and 2.5), and clade 7 is divided into 2 subclades (7.1 and 7.2). Subclade 2.1 is further divided into 2. To deal with this high level of genetic diversity, 2 general vaccine approaches are currently explored. The first approach is based on using particular strains or combinations of strains (multivalent) selected from a geographic region where the vaccine is intended for use [8] [9] [10] [11] [12] [13] . For example, the World Health Organization (WHO) has already created 22 seed vaccine strains for use in different geographic regions. These strains cover (sub)clades 1.1, 1, 2.1, 2.1.3.2, 2.2, 2.2.1.1, 2.2.1, 2.3.2.1, 2.3.4, 4, and 7.1 [8] . The second approach is to construct either a consensus or an ancestral HA sequence reconstructed on the basis of an evolutionary model [14, 15] . Such sequences have the advantage of being central and most similar to currently circulating strains of interest and may have enhanced potential for eliciting cross-reactive responses. However, as both consensus and ancestral sequences are derived and not actual sequences, expression, antigenicity, and biological activity require careful characterization before use in a vaccine [16] .
In the present study we combined both approaches by choosing an A/Thailand/1(KAN)-1/2004 H5N1 strain, whose HA sequence is the closest to the consensus sequence among diverse WHO-recommended H5 vaccine strains analyzed ( Figure 1 ). We primed BALB/c mice twice with DNA plasmid encoding H5 HA from this single strain and boosted once with virus-like particles (VLPs) from the same strain. We demonstrated that this prime-boost regimen induces antibody responses that cross-neutralize all reported clades and subclades of HPAI H5N1 viruses and HA peptide-specific CD8 T-cell responses and protects mice from high lethal dose of divergent HPAI H5N1 challenge by both active and passive immunizations. Moreover, we demonstrated that the cross-divergent H5 neutralizing antibodies are directed to the head region of HA and block both virus attachment and postattachment. Thus, this is the first report that a heterologous prime-boost regimen with HA from a single HPAI H5N1 strain could elicit antibody responses that cross-neutralize all reported clades and subclades of HPAI H5N1 viruses and that such antibody responses are directed to the head region of HA.
MATERIALS AND METHODS

Active and Passive Immunization and Challenge
Female BALB/c mice (6-8 weeks old) were primed twice intramuscularly with codon optimized H5 HA DNA and boosted once intraperitoneally with VLPs expressing H5 HA from the A/Thailand/1(KAN)-1/04 strain. Control mice were primed twice with empty vector and boosted with human immunodeficiency virus type 1 (HIV-1) gag alone VLPs. For the sake of brevity in the remaining text, we use the terms "TH-DDV" for 2 DNA injections followed by 1 VLP injection of H5 HA from an A/Thailand/1(KAN)-1/2004 strain and "control-DDV" for 2 injections of empty vector followed by 1 injection of HIV-1 Figure 1 . Phylogenetic analysis of hemagglutinin gene of H5 avian influenza viruses. Using the neighbor-joining method, the bootstrap consensus tree inferred from 1000 replicates was analyzed. Most strains were chosen from the World Health Organization-suggested vaccine strains. The A/Thailand/1 (KAN-1)/2004 strain and consensus sequence are shown in blue. *Challenge strains. gag alone VLPs. Two weeks postboost, mice were challenged intranasally with 100 MLD 50 (the dose lethal for 50% of mice) of H5N1 strains A/Cambodia/P0322095/2005(CB/05) and A/Shenzhen/406H/2006(SZ/06) and monitored for 14 days. Mice losing 30% of their initial weight were euthanized and scored as dead. Viruses in lung tissues of infected mice were titrated at 3 and 6 days postinfection.
For passive immunization and challenge, immune and control sera were administered intraperitoneally into recipient mice, mice were challenged, and signs of illness and body weight were monitored daily for 14 days.
Pseudotype-based neutralization (PN) assay [17] and intracellular cytokine staining [18] were performed as previously described. The attachment and the postattachment assays were performed as described elsewhere [19] . A more complete description of the Materials and Methods is available in the Supplementary Data.
RESULTS
Elicitation of Antibody Responses That Cross-Neutralize All Reported Clades and Subclades of H5N1 Viruses
To evaluate the breadth of neutralizing antibody responses, groups of female BALB/c mice were primed twice with plasmid encoding H5 HA from an A/Thailand/1(KAN)-1/2004 strain and boosted once with VLPs expressing the same HA (TH-DDV) or primed with empty vector and boosted with gag alone VLPs (control-DDV). Immune sera from TH-DDV mice and sera from control-DDV mice were collected 14 days postboost and analyzed for their ability to cross-neutralize 17 H5N1 pseudotypes covering all reported H5 clades and subclades as previously described [17, 18] . Figure 2 shows that, remarkably, TH-DDV sera, but not control-DDV sera, cross-neutralize all H5N1 pseudotypes, with the IC 50 [20] .
Elicitation of HA Peptide-Specific CD8 T-Cell Responses
To test whether TH-DDV could elicit HA-specific CD8 T-cell response, splenocytes from TH-DDV and control-DDV mice were assayed against 2 H-2 K d -restricted HA peptides (IYST VASSL and LYEKVRLQL) as described previously [18] . Compared to control-DDV mice, TH-DDV mice exhibited statistically Table 1 are shown. IC 50 (dashed line) is defined as the reciprocal dilutions that result in 50% inhibition. Data collected from 3 independent experiments are presented as mean ± SEM; error bars represent standard error of the mean (SEM). VSV pseudotype was used as a negative control. The virus strains and (sub)clades in parentheses are shown and the abbreviations of H5N1 strains are listed in Supplementary Table 1 . Abbreviation: ND, not detected.
significant HA peptide-specific CD8 T-cell responses. On average, 2.42%, 0.15%, and 1.41% of CD8 T cells from TH-DDV mice secreted interferon gamma (IFN-γ), interleukin 2 (IL-2), and tumor necrosis factor alpha (TNF-α), respectively ( Figure 3B-D) . In addition, on average 0.14% of HA peptide-specific CD8 T cells secreted all 3 cytokines (IFN-γ, IL-2, and TNF-α), and 1.2% of HA peptide-specific CD8 T cells secreted both IFN-γ and TNF-α ( Figure 3E ). Thus, we conclude that the TH-DDV elicits both broadly neutralizing antibody and specific CD8 T-cell responses.
Protection Against High Lethal Dose of Divergent H5N1 Challenge Elicited by TH DDV
To test whether TH-DDV would confer protection against HPAI H5N1 challenge, TH-DDV and control-DDV mice were intranasally challenged with 100 MLD 50 heterologous strains A/Cambodia/P0322095/2005 (CB/05) and A/Shenzhen/406H/ 2006(SZ/06), respectively. After the challenge, body weight and survival were monitored for 14 days. In addition, viruses in the lung tissues were titrated at days 3 and 6 after the infection. Beginning at day 3 postchallenge, control-DDV mice became sick and all mice died between days 6 and 8. In contrast, after the challenge, TH-DDV mice did not show any sign of illness or weight loss and all survived ( Figure 4A ). The lung tissues in control-DDV mice exhibited high virus titers, whereas no virus was detected in the lung tissues of TH-DDV mice ( Figure 4B ). Thus, we conclude that TH-DDV indeed confers protection against high lethal dose challenge of heterologous HPAI H5N1 viruses.
To determine if the protection was mediated by immunized sera, female BALB/c mice were intraperitoneally injected with 700 μL of combined TH-DDV or control-DDV sera. Neutralization titers of TH-DDV and control-DDV sera were measured by hemagglutination inhibition (HI), microneutralization (MN), and PN assays. As shown in Figure 4C , TH-DDV sera exhibited high neutralization titers against CB/05 and low neutralization titers against SZ/06. In contrast, control-DDV sera did not exhibit any neutralization activity. Twenty-four hours after passive immunization, mice were challenged with the same 100 MLD 50 H5N1 strains as described above. Figure 4D shows that after the challenge, all mice injected with control-DDV sera became sick and died within 8 days, whereas mice that received TH-DDV sera had no weight loss and all survived. Similarly, the lung tissues of mice injected with control-DDV sera exhibited high virus titers, whereas no virus was detected in the lung tissues of mice injected with TH-DDV sera ( Figure 4E ). Thus, these results indicate that TH-DDV sera alone are sufficient to confer protection from high lethal dose H5N1 challenge.
Broadly Cross-H5 Neutralizing Antibody Responses Are Directed Against the Head Region
Previously, Wei et al showed that priming with plasmid encoding H1 HA and boosting with seasonal influenza vaccine induced cross-divergent H1 neutralizing antibody responses that were directed to the conserved stem region [20] . Ledgerwood et al demonstrated that priming with H5 HA plasmid and boosting with monovalent inactivated H5N1 virus (MIV) induced protective neutralizing antibodies also directed to the conserved stem region [21] . Therefore, to determine whether the broadly cross-divergent H5 neutralizing antibody responses C, Antibody responses of combined TH-DDV sera or control-DDV sera against CB/05 and SZ/06 were measured by HI (hemagglutination inhibition), MN (microneutralization) and PN ( pseudotype-based neutralization) assays before passive immunization. Data collected from 3 independent experiments are presented as mean ± SD or IC 50 along with the 95% confidence intervals in parentheses; error bars represent standard deviation (SD). D, Passive immunization of immune sera confers protection against divergent H5N1 virus challenge. To assess the protective effect of TH-DDV sera, 24 mice (12 mice per group) received combined TH-DDV sera and 24 mice (12 mice per group) received control-DDV sera. Twenty-four hours later, mice were intranasally challenged with 100 MLD 50 CB/05 and SZ/06, respectively. Body weight (upper panels) and survival (lower panels) were monitored and recorded for 14 days after virus challenge. Body weight is presented as mean ± SD; error bars represent standard deviations (SD). E, Virus titers in lung tissues at 3 and 6 days postinfection between mice receiving combined TH-DDV sera and mice receiving combined control-DDV sera.
elicited by TH-DDV are also directed to the stem region, we first performed Western blot analysis with TH-DDV sera against 16 H5 HA and VSV control. Figure 5A shows that TH-DDV sera bound both the HA1 and HA2 of 16 H5 HA tested, but not VSV control, indicating that immune sera elicited by TH-DDV contain both HA1 and HA2 binding antibodies.
To dissect cross-divergent H5 neutralizing antibody responses in TH-DDV sera, we generated a panel of HA and NA (neuraminidase) pseudotypes expressing various H5 HA head/stem chimera among high ( pTH/04 and pDk/GX/04), intermediate ( pID/05 and pSZ/06), and low ( pCm/HK/07) susceptible strains (Supplementary Table 2 ). In all cases we found that cross-divergent H5 neutralizing antibody responses are directed against the head region; that is, regardless of which stems were linked with, if the head regions were from high susceptible strains, high cross-neutralization titers were detected ( Figure 5B . Thus, taken together, we conclude that, unlike those reported by Wei et al [20] and Ledgerwood et al [21] , cross-divergent H5 neutralizing antibody responses are directed against the head region even though cross-H5 binding antibodies bind both HA1 and HA2.
Effect of Cross-Divergent H5 Neutralizing Antibodies on Attachment and Postattachment of Virus Entry
We next dissected the effect of cross-divergent H5 neutralizing antibodies on attachment and postattachment of virus entry. To accomplish this, we performed attachment and postattachment assays using the panel of HA and NA pseudotypes expressing various H5 HA head/ stem chimera shown in Supplementary Table 2 . Figure 6A and 6B show that TH-DDV sera, but not control-DDV sera, significantly blocked attachment of all H5N1 pseudotypes expressing either wild-type or head/stem chimeras of H5 HA in a dose-dependent manner. Parallel to the inhibition found in neutralization assays ( Figure 5B), the blockage of the virus attachment was also directed to the head region; that is, regardless of which stems were linked with, if the head regions were from high susceptible strains, a high degree of blockage was detected (light blue and purple colors in Figure 6A) ; if the head regions were from intermediate susceptible strains, an intermediate degree of blockage was found (coffee and burgundy colors in Figure 6A) ; if the head regions were from low susceptible strains, low blockage was found (blue and orange colors in Figure 6A ). However, there was no statistically significant difference between low and intermediate degrees of blockage. Figure 6C and 6D show that TH-DDV sera, but not control-DDV sera, significantly blocked postattachment of H5N1 pseudotypes, whose H5 HA head was derived from high or intermediate susceptible strains, but not low susceptible strains. Parallel to the inhibition found in neutralization assays ( Figure 5B), the blockage of the postattachment was also directed to the head region; that is, regardless of which stems were linked with, if the head regions were from high susceptible strains, a high degree of postattachment blockage was detected (light blue and purple colors in Figure 6C) ; if the head regions were from intermediate susceptible strains, intermediate degree of post-attachment blockage was found (coffee and burgundy colors in Figure 6C ); if the head regions were from low susceptible strains, no blockage was found (orange and blue colors in Figure 6C ). To further test whether these attachment and postattachment blockages are specific against HA, 2 additional sets of control experiment were carried out. We found that neither TH-DDV nor control-DDV sera block the attachment and the postattachment of VSV pseudotype ( Figure 6E ). We found that rabbit anti-N1 NA immune sera do not block the attachment or the postattachment of H5N1 pseudotypes ( Figure 6F) .
Thus, taken together, these results strongly indicate that the blockages of the attachment and the postattachment by TH-DDV sera are HA specific and directed to the head region of HA. Furthermore, a high degree of neutralization against high susceptible strains results from high degrees of blockage of both attachment and postattachment; an intermediate degree of neutralization against intermediate susceptible strains results from intermediate degrees of blockage of both attachment and postattachment; and a low degree of neutralization against low susceptible strains results only from the low degrees of blockage of attachment, but no blockage of postattachment.
DISCUSSION
As the major viral protein to elicit neutralizing antibody responses, HA is also the most variable influenza virus protein.
For HPAI H5N1 viruses, during the past 16 years H5 HA has evolved into 10 genetically distinct clades. Among them, clades 2 and 7 have further evolved into subclades [7] . This variability poses a great scientific challenge in HA-based influenza vaccine development against diverse HPAI H5N1 viruses. In the present study, we tested the immunogenicity and protection elicited with a H5 HA from a single H5N1 strain, whose sequence is the closest to the consensus HA among diverse WHO-recommended H5 vaccine strains (Figure 1) , in a heterologous prime-boost vaccination.
Perhaps the most important findings in the present study are that TH-DDV induces antibody responses that cross-neutralize all reported H5 clades and subclades (Figure 2 and Supplementary Table 1 ) and HA peptide-specific CD8 T-cell responses ( Figure 3 ) and confers protection against high lethal dose of divergent H5N1 challenge by both active and passive immunizations (Figure 4) . Thus, much broader cross-divergent H5 neutralizing antibody responses elicited with TH-DDV represents a significant improvement from many previous studies including our own [11, 14, 15, 18, [22] [23] [24] .
Although the present study focused on TH-DDV as compared to control-DDV, in our preliminary study we also compared cross-neutralization activity elicited with (1) DNA alone (TH-DDD), VLP alone (TH-VVV) vs DNA-VLP (TH-DDV) prime boost; (2) 1 injection of DNA followed by VLP boost (TH-DV) vs 2 injections of DNA followed by VLP (TH-DDV); and (3) 2 injections of DNA followed by VLPs between H5 HA from A/Thailand/(KAN-1)/2004 clade 1 (TH-DDV) vs A/ Turkey/65596/2006 subclade 2.2.1 (TU-DDV). We found that (1) 2 DNA injections followed by VLPs elicits far better crossneutralization activity than 3 injections of DNA alone or VLPs alone; (2) 2 DNA injections followed by VLPs elicits far better cross-neutralization activity than 1 DNA injection followed by VLPs; and (3) In addition, we compared cross-neutralization activity elicited with 2 DNA injections followed by intraperitoneal VLP injection vs 2 DNA injections followed by intramuscular VLP injection. We found no significant difference in neutralization antibody titers (Wang et al, data not shown).
Therefore, likely, the significant improvement of the breadth of neutralizing antibody responses is not only due to the choice of the particular single strain, but also due to the twice DNA priming in the present study. It has been shown that multiple DNA priming leads to increased number and diversity of antigenspecific CD4 T-cell clones, which in turn stimulates B cells to secrete antibodies with greater magnitude and diversity [20] .
Another important finding in the present study is that the cross-divergent H5 neutralizing antibody responses elicited with this prime-boost regimen are directed to the head region of HA, which block both attachment and postattachment steps of virus entry ( Figures 5B, 6A, and 6C ). This finding is somehow unexpected, as conserved epitopes that are recognized by broadly neutralizing monoclonal antibodies such as C179, CR6261, F10, CR8020, FI6, CR9114, and 12D1 reside in the stem region of HA [25] [26] [27] [28] [29] [30] [31] [32] . Various vaccine strategies have taken advantage of this feature to drive antibody responses toward this conserved region in the development of "universal" influenza vaccines [33] [34] [35] [36] . Nevertheless, human and mouse monoclonal antibodies that recognize conserved epitopes in the head region of HA have also been reported [17, 19, [37] [38] [39] [40] [41] [42] [43] . For example, Whittle et al [39] described a subtype-specific broadly neutralizing antibody, CH65, isolated from single plasma cells of an individual vaccinated against seasonal influenza, that neutralizes 30 of 36 H1N1 strains from the past 30 years. The epitope recognized by antibody CH65 is in the receptor binding site (RBS) that overlaps with the antigenic site of Sb. We recently reported 2 human monoclonal antibodies, 65C6 and 100F4, isolated from a H5N1-infected individual, that neutralize H5N1 strains derived from all clades and subclades of H5 HA with a high degree of potency except for subclade 7.2.
The epitopes recognized by these 2 antibodies reside in the head region of H5 HA outside RBS [17, 42] . Thus, our present findings are consistent with the presence of conserved epitopes in the head region among HPAI H5N1 viruses and with the findings in a recent Food and Drug Administration-approved phase 1/2 human clinical study, in which 2 high doses of H5N1 VLP vaccination induced antibody responses against both HA1 and HA2 regions [44] , but were different from the cross-divergent H1 antibody responses elicited with DNA prime and seasonal influenza boost reported by Wei et al [20] and from the crossdivergent H5 antibody responses elicited with DNA prime and H5N1 MIV boost in humans reported by Ledgerwood et al [21] . In the latter 2 studies, using both competition neutralization and enzyme-linked immunosorbent assays, the majority of cross-divergent H1 or H5 antibody responses bind to the conserved stem region. At this time, it is not clear what accounts for the discrepancy. This may be due to different evolution of HA between H1 and H5 subtypes, different boost modalities, and/or different assay systems. Investigation is currently under way to determine the conserved neutralization epitopes recognized by immune sera elicited by this prime-boost regimen.
Epidemiology studies showed that, unlike human influenza H1N1 and H3N2 strains that usually have few dominant strains circulating worldwide at a given time period, various clades and subclades of HPAI H5N1 viruses are evolving and cocirculating in the different parts of the world [7] . Moreover, 2 recent studies indicated that with few mutations in H5 HA, H5N1 variants can spread through aerosol among ferrets, which are the best model to study virus spread in humans [4, 5] . Thus, the demonstration that this prime-boost regimen elicits antibody responses that cross-neutralize all reported H5 clades and subclades and confer protection against high lethal dose of divergent HPAI H5N1 challenge in mice in the present study makes this regimen a promising pan-H5 vaccine candidate against divergent HPAI H5N1 strains in humans as well as in chickens. A similar approach could be used to develop pan-H7 vaccine against diverse H7 strains including a recent outbreak of H7N9 strains in China.
Finally, DNA-based vaccination has been shown to be safe and well tolerated in various human trials against various pathogens [45] [46] [47] [48] . DNA plasmid has been shown to be a good priming regimen in heterologous prime-boost vaccination in animals and in humans against influenza A viruses [20, 21] . In addition, influenza VLPs against pandemic influenza A (H1N1) 2009 and HPAI H5N1 have also been shown to be safe and immunogenic in human phase 1/2 clinical trials [44, 49] . Furthermore, a recent study by Wei et al [50] also shows that even in mice and ferrets that were previously infected or vaccinated, broadly neutralizing antibody responses could still be induced with DNA prime and inactivated vaccine boost. Thus, the demonstration that TH-DDV elicits broad antibody responses that confer protection against lethal challenge of divergent HPAI H5N1 viruses in mice in the present study supports further development of this prime-boost regimen in ferrets and in humans as well as in chickens.
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